Skip to content

Understanding how Livex Tablets protect Your Liver and Help it heal from damage

The Role of Tab. Livex in Protecting and Restoring Liver Function - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089109
Enrollment
60
Registered
2025-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K769- Liver disease, unspecified

Interventions

None listed

Sponsors

Dr Deodatta Bhadlikar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age: Adults aged 18 to 70 years inclusive. 2.Clinical Diagnosis of Liver Dysfunction including any of the following: Mild to moderate non-alcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease (AFLD) (stable condition) Hepatitis (viral or drug-induced mild to moderate severity) Compensated liver cirrhosis Elevated liver enzymes (ALT AST ALP or GGT) and mildly elevated total bilirubin 3.Stable Medical Condition: Participants with chronic conditions (e.g. diabetes hypertension) must be on stable treatment for at least 3 months. 4.Willingness to participate and provide written informed consent. 5.Able to comply with study procedures and follow-up schedule.

Exclusion criteria

Exclusion criteria: 1.Decompensated liver disease including: Ascites Hepatic encephalopathy Variceal bleeding Child-Pugh Score more than B 2.Severe hepatic impairment 3.Known hepatocellular carcinoma or any other active malignancy. 4.History of organ transplantation (including liver kidney etc.) 5.Severe renal impairment 6.Uncontrolled chronic disease (e.g. unstable angina recent MI severe COPD) 7.Ongoing alcohol abuse or substance use disorder (within the past 6 months) 8.Pregnant or lactating women or those planning pregnancy during the study period. 9.Use of other herbal supplements hepatoprotective agents or investigational drugs within 30 days prior to study entry.

Design outcomes

Primary

MeasureTime frame
Change in Liver Function ParametersTimepoint: 60 days

Secondary

MeasureTime frame
1.Change in Liver Synthetic Function 2. Quality of Life (QoL) Assessment 3.Change in Appetite and Nutritional Status 4.Adverse Events MonitoringTimepoint: 60 days

Countries

India

Contacts

Public ContactDr Devyani Bhadlikar

Sardar Ajit Singh Smriti Ayurveda Mahavidyalaya Raisen Road Bhopal Madhya Pradesh

drdevyani.bhadlikar@gmail.com9920467783

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026